Trials / Terminated
TerminatedNCT00664378
Efficacy Study of CYT997 in Multiple Myeloma
A Prospective, Single-arm, Two-stage, Open-label Phase II Trial of CYT997 in Relapsed and Refractory Multiple Myeloma
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 5 (actual)
- Sponsor
- Gilead Sciences · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a clinical research study that is designed to test the safety of CYT997 when given to patients with multiple myeloma and to test if CYT997 has any activity against that cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CYT997 | Intravenous infusion (24h); 202mg/m2 on days 1 and 8 of a 21 day cycle |
Timeline
- Start date
- 2008-01-01
- Primary completion
- 2011-02-01
- Completion
- 2011-02-01
- First posted
- 2008-04-22
- Last updated
- 2018-06-08
Locations
1 site across 1 country: Australia
Source: ClinicalTrials.gov record NCT00664378. Inclusion in this directory is not an endorsement.